Morgan Stanley downgraded NYSE:AVTR to an Equal-Weight rating, reflecting concerns over financial performance.
Avantor’s Q1 2025 earnings report showed an adjusted EPS of 23 cents, but revenues fell to $1.58 billion, missing estimates.
The company’s stock experienced a significant drop of 16.6% following the earnings announcement and downgrade.
Avantor, Inc. (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries. The company operates through various segments, including Laboratory Solutions and Bioscience Production. Avantor faces competition from companies like Thermo Fisher Scientific and Merck KGaA.
On April 29, 2025, Morgan Stanley downgraded Avantor to an Equal-Weight rating, with the stock priced at $12.68. This downgrade reflects a shift from the previous Overweight rating. The downgrade comes amid financial challenges, as highlighted by Avantor’s recent earnings report.
Avantor’s first-quarter 2025 earnings showed an adjusted EPS of 23 cents, a 4.5% increase from the previous year, aligning with the Zacks Consensus Estimate. However, the company’s GAAP EPS remained flat at 9 cents year over year. Despite meeting earnings expectations, Avantor’s revenues fell to $1.58 billion, a 5.9% decline from the previous year, missing the Zacks Consensus Estimate by 1.7%.
The revenue decline was influenced by unfavorable foreign currency translation and the divestiture of Avantor’s Clinical Services, leading to an organic sales decline of 2.2%. This contributed to a significant 16.6% drop in Avantor’s stock by the end of Friday’s trading. The Laboratory Solutions segment reported net sales of $1.07 billion, an 8% decrease year over year, with organic sales declining by 2.9%.
Despite these challenges, Avantor’s Bioscience Production segment demonstrated strong growth amid ongoing macroeconomic pressures. Currently, AVTR is priced at $12.73, reflecting a slight increase of 0.28% or $0.035. The stock has fluctuated between $12.62 and $12.74 today, with a market capitalization of approximately $8.67 billion and a trading volume of 1,650,299 shares on the NYSE.
